Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2018

SKU ID : GMD-GMDHC10127IDB 10961645

Publishing Date : 30-Jan-2018

No. of pages : 63

PRICE
2000
6000


  • Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2018

    Summary

    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2018, provides an overview of the Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline landscape.

    Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of finger when pressed (known as pitting edema), discoloration and darkening of skin around the ulcer (known as hemosiderosis), hardened skin around the ulcer, which may make leg feel hard and resemble the shape of an upside-down champagne bottle (known as lipodermatosclerosis), small, smooth areas of white skin, which may have tiny red spots (known as atrophie blanche).

    Report Highlights

    Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural ulcer) (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Venous Leg Ulcers (Crural ulcer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 5, 1, 4 and 2 respectively.

    Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer) (Dermatology).
    - The pipeline guide reviews pipeline therapeutics